Geneva, April 27 -- International Clinical Trials Registry received information related to the study (NCT07533747) titled 'PRECISE Phenotyping to Guide Therapies for Coronary Microvascular Dysfunction' on April 10.

Study Type: Interventional

Study Design: Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).

Primary Sponsor: King's College London

Condition: Coronary Microvascular Dysfunction (CMD)

Intervention: Drug: Empagliflozin 10mg OD

Recruitment Status: Not recruiting

Phase: Phase 3

Date of First Enrollment: May 2026

Target Sample Size: 100

To know more, visit https://clinicaltrials.gov/study/NCT07533747

Disclaimer: Curated by HT Syndication....